Back to Search
Start Over
Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?
- Source :
- American Journal of Cardiovascular Drugs. 19:229-235
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Cholesteryl ester transfer protein (CETP) plays an important role in lipid metabolism and has presented an attractive target for drug development, primarily resting on the hope that CETP inhibition would reduce cardiovascular events through its ability to increase levels of high-density lipoprotein cholesterol (HDL-C). However, clinical development of CETP inhibitors has proven disappointing, with a spectrum of results spanning from evidence of harm, to futility, to only modest benefit in large-scale cardiovascular outcomes trials. A number of additional insights from genomic studies have suggested potential benefits from these agents in specific clinical settings. We review the current state of CETP inhibitors as an approach to targeting cardiovascular risk.
- Subjects :
- Disease
030204 cardiovascular system & hematology
Pharmacology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Pharmacotherapy
Drug Development
Risk Factors
Cholesterylester transfer protein
Animals
Humans
Medicine
Pharmacology (medical)
030212 general & internal medicine
biology
Cholesterol
business.industry
Anticholesteremic Agents
Cholesterol, HDL
Lipid metabolism
General Medicine
Cetp inhibition
Cholesterol Ester Transfer Proteins
carbohydrates (lipids)
Drug development
chemistry
Cardiovascular Diseases
biology.protein
lipids (amino acids, peptides, and proteins)
Cardiology and Cardiovascular Medicine
business
Cardiovascular outcomes
Subjects
Details
- ISSN :
- 1179187X and 11753277
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- American Journal of Cardiovascular Drugs
- Accession number :
- edsair.doi.dedup.....b7ce98821abeec393313cab681b4e73e